Supporting information

The Synthesis and Biological Evaluation of Mycobacterial *p*-Hydroxybenzoic Acid Derivatives (*p*-HBADs)

Jean Bourke^[a], Corinna F. Brereton^[b], Stephen V. Gordon^[c], Ed C. Lavelle^{*[b]} and

^aEoin M. Scanlan^{*[a]}

e-mail: <u>eoin.scanlan@tcd.ie</u>

Contents:

| Figure 3 | 53 |
|--|-----|
| ¹ H and ¹³ C NMR Spectra of Compound 2 S | 34 |
| ¹ H and ¹³ C NMR Spectra of Compound 3 S | 5 |
| ¹ H and ¹³ C NMR Spectra of Compound 4 S | 6 |
| ¹ H and ¹³ C NMR Spectra of Compound 5 S | 7 |
| ¹ H and ¹³ C NMR Spectra of Compound 6 S | 8 |
| ¹ H and ¹³ C NMR Spectra of Compound 7S | 9 |
| ¹ H and ¹³ C NMR Spectra of Compound 8S | 510 |
| ¹ H and ¹³ C NMR Spectra of Compound 9 S | 511 |
| ¹ H and ¹³ C NMR Spectra of Compound 10 S | 512 |
| ¹ H and ¹³ C NMR Spectra of Compound 11 S | 13 |
| ¹ H and ¹³ C NMR Spectra of Compound 12 S | 514 |
| ¹ H and ¹³ C NMR Spectra of Compound 13 S | 15 |
| ¹ H and ¹³ C NMR Spectra of Compound 14 S | 516 |
| ¹ H and ¹³ C NMR Spectra of Compound 15 S | 517 |
| ¹ H and ¹³ C NMR Spectra of Compound 16 S | 518 |

| ¹ H and ¹³ C NMR Spectra of Compound 17 | .S19 |
|--|------|
| ¹ H and ¹³ C NMR Spectra of Compound 18 | .S20 |
| ¹ H and ¹³ C NMR Spectra of Compound 20 | .S21 |
| ¹ H and ¹³ C NMR Spectra of Compound 21 | .S22 |
| ¹ H and ¹³ C NMR Spectra of Compound 22 | .S23 |
| ¹ H and ¹³ C NMR Spectra of Compound 23 | S24 |



Figure 3. Flow cytometry data. *p*-HBADs suppress IFN- γ production by CD4+ T cells. Splenocytes were incubated with medium, *p*-HBADs alone or in the presence of anti-CD3e. Cells were incubated for 72 h and T cell proliferation and IFN- γ production was assessed.

¹H of compound 2





¹H of compound 3



13 C of compound 3



¹H of compound 4









 $^{1}\mathrm{H}$ of compound 6





¹H of compound 7



 13 C of compound 7



¹H of compound 8









¹H of compound 10



























¹H of compound 15















 13 C of compound 18







 13 C of compound 19





 $^{13}\mathrm{C}$ of compound 20







